Medicus Pharma Submits Phase 2b/3 Teverelix Protocol to FDA

A protocol submission to FDA is doing double duty for Medicus Pharma: the September 29 filing for Teverelix® is simultaneously a regulatory optimization exercise and a licensing prospectus. The proposed seamless Phase 2b/3 registration-intent design, if accepted, would compress the planned development population from approximately 1,500 patients to approximately 600, restructuring the program around a single pathway that covers dose optimization, androgen suppression, and prospective cardiovascular differentiation in advanced prostate cancer patients at elevated CV risk.

The stage-gated structure is central to the capital logic. An initial cohort of approximately 80 randomized patients would absorb and replace the previously FDA-cleared 40-patient open-label dose-optimization study. Predefined continuation criteria must be met before the program expands to approximately 528 additional patients, with early-stage enrollees contributing to final registration analyses. Medicus has been explicit that it does not intend to fund clinical execution independently; the submission is designed to produce a regulatory-defined pathway that a licensing or strategic partner would then operationalize.

For regulatory affairs leads tracking adaptive trial design, the submission reflects a deliberate sequencing of FDA engagement ahead of any partnering conversation. Medicus filed the protocol following its September 8, 2026 portfolio strategy announcement, under which the company is concentrating internal resources on programs offering the strongest risk-adjusted profile. The Teverelix APC program is being positioned as partner-ready at the regulatory design stage rather than after a standalone Phase 2b readout, a model that shifts the negotiating dynamic by presenting prospective partners with an FDA-engaged development blueprint rather than a completed but unregistered dataset.

Teverelix is an investigational long-acting GnRH antagonist. The cardiovascular differentiation angle is material to the program's positioning: the trial is specifically designed to enroll APC patients at increased CV risk, a population where GnRH antagonists have drawn regulatory and clinical interest relative to agonist-based androgen deprivation therapy. Whether FDA concurs with the proposed seamless architecture will determine whether that differentiation story can be pursued within a single registration-intent study or requires a more conventional sequential design.

Medicus has acknowledged the material uncertainties: FDA agreement with the protocol is not assured, the optimized pathway may not ultimately support registration, and a licensing transaction may not be concluded on acceptable terms or at all.

The FDA's response to the protocol submission will set the ceiling on what Medicus can credibly offer a prospective partner and define the enrollment and timeline commitments any licensing agreement would need to absorb.

Source: Medicus Pharma via GlobeNewswire, September 29, 2026.